# generate_tests\Test mAB\IgG2-K-002.txt
# Generated sample - 10106H|ascrinvacumab|Homo sapiens||H-GAMMA-2 (VH (1-118) [D1] + CH1 (119-216) [D2] + CH2 (229-337) [D3] + CH3 (338-442) [D4])|||||||444|444|||MW undefined|MW undefined| - Trypsin - 75%
GLEWIGYIYYSGSTYYNPSLK
VTISVDTSK
NQFSLK
LSSVTAADTAVYYCAR
ESVAGFDYWGQGTLVTVSSASTK
GPSVFPLAPCSR
STSESTAALGCLVK
CCVECPPCPAPPVAGPSVFLFPPKPK
DTLMISR
TPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAK
EEQFNSTFR
VVSVLTVVHQDWLNGK
GLPAPIEK
NQVSLTCLVK
WQQGNVFSCSVMHEALHNHYTQK
SLSLSPGK
# Generated sample - 10106H|ascrinvacumab|Homo sapiens||H-GAMMA-2 (VH (1-118) [D1] + CH1 (119-216) [D2] + CH2 (229-337) [D3] + CH3 (338-442) [D4])|||||||444|444|||MW undefined|MW undefined| - Chymotrypsin - 75%
QESGPGL
VKPSQTL
TCTVSGGSISSGEY
IRQHPGKGL
KSRVTISVDTSKNQF
SSVTAADTAVY
CARESVAGF
VTVSSASTKGPSVF
APCSRSTSESTAAL
PEPVTVSW
TSGVHTF
SSVVTVPSSNF
PPKPKDTL
ISRTPEVTCVVVDVSHEDPEVQF
VDGVEVHNAKTKPREEQF
RVVSVL
KCKVSNKGL
PAPIEKTISKTKGQPREPQVY
PPSREEM
PSDIAVEW
KTTPPM
DSDGSF
TVDKSRW
QQGNVF
# Generated sample - 10106H|ascrinvacumab|Homo sapiens||H-GAMMA-2 (VH (1-118) [D1] + CH1 (119-216) [D2] + CH2 (229-337) [D3] + CH3 (338-442) [D4])|||||||444|444|||MW undefined|MW undefined| - LysC - 75%
QVQLQESGPGLVK
PSQTLSLTCTVSGGSISSGEYYWNWIRQHPGK
NQFSLK
LSSVTAADTAVYYCARESVAGFDYWGQGTLVTVSSASTK
GPSVFPLAPCSRSTSESTAALGCLVK
CCVECPPCPAPPVAGPSVFLFPPK
PREEQFNSTFRVVSVLTVVHQDWLNGK
GLPAPIEK
GQPREPQVYTLPPSREEMTK
GFYPSDIAVEWESNGQPENNYK
TTPPMLDSDGSFFLYSK
SRWQQGNVFSCSVMHEALHNHYTQK
# Generated sample - 10106H|ascrinvacumab|Homo sapiens||H-GAMMA-2 (VH (1-118) [D1] + CH1 (119-216) [D2] + CH2 (229-337) [D3] + CH3 (338-442) [D4])|||||||444|444|||MW undefined|MW undefined| - Aspecific - 75%
ESGPGLVKPSQTLSL
LVKPSQTLSLT
SSGEYYWN
YYWNWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRV
YWNWIRQHPGKGLEWIG
WIRQHPGKGLEWIGYIYYSGS
QHPGKGLEWIGYIYYSGST
KGLEWIGYIYYSGSTYYNPSLKSRV
EWIGYIYYSGSTYYNPSLKSRVTISVDT
SGSTYYNPSL
SGSTYYNPSLKSRVTISVDTSKNQFSL
TYYNPSLKSRVTISVD
RVTISVDTSKNQFSLKLSSVTAADTAVYYCAR
VTISVDTSKNQFSLKLSSVTAADTAV
NQFSLKLSSVTAADTAVYYCARESVAGFDYWGQGTLVT
FSLKLSSVTAADTAV
KLSSVTAADTAVYYCARESVAGFDYWGQGTLVTVSSASTK
LSSVTAADTAVYYCARESVAGFDYWG
SVTAADT
SVTAADTA
ADTAVYY
RESVAGFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTS
VAGFDYWG
AGFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTA
DYWGQGTLVTVSS
GQGTLVTVSSASTK
SASTKGPSVFPLAPCSRST
SVFPLAPCSRSTSESTAALGCLVKDY
VFPLAPCSRSTSESTA
FPLAPCSRSTSESTAALGCLVK
FPLAPCSRSTSESTAALGCLVKDYF
PLAPCSRSTSESTAAL
STSESTAALGCLVKDYFP
ESTAALGCLVKDYFPEPVTVSWNS
STAALGCLVKDYFPEPVTVSWNSGA
TAALGCL
ALGCLVKDYFPEPVTVSWNSGALTS
PVTVSWNSGALT
LTSGVHTFPAVLQSSGLYSLSSVVTV
LTSGVHTFPAVLQSSGLYSLSSVVTVP
SGVHTFPAVLQSSGLYSLSSVVTVPS
VHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDH
PAVLQSSGLY
AVLQSSGLYSLSS
AVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNT
GTQTYTCNVDHKPSNTKV
TQTYTCNVDHKPSNTKV
TQTYTCNVDHKPSNTKVDKT
TYTCNVDHKPSNTKVDKTVERKCCVECPPCP
YTCNVDHKPSNTK
YTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSV
DHKPSNTKVDKTVERKCCVECPPCPAPPVAGPS
SNTKVDKTVERKCCVECPPCPAPPVAGPSVF
KVDKTVERKCCVECPPCPAPPV
RKCCVECPPCPAPPVA
CCVECPPCPAPP
PPCPAPPVAGPSVFLFPPKPKDTLMI
CPAPPVAGPSVFLFPPKPKDTLMISRTPE
AGPSVFLFPPKPKDTLMISRT
FLFPPKPKDTLMISRTP
PPKPKDTLMISRTPEVTCVVVDVSHEDP
PKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNW
CVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPRE
VDVSHEDPEVQFNWYVDGVEVHN
EDPEVQFNWY
FNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVH
GVEVHNAKTKPR
EEQFNST
LTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQP
KVSNKGLP
LPAPIEKTISKTKGQPREPQVYTL
APIEKTISKTKGQPREPQVYTLPPSREE
EKTISKTKGQ
EKTISKTKGQPREPQVYTLPPSREEMTKNQV
QPREPQVYTLPPSRE
NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
FYPSDIAVEWESNGQPENNYKTTPPML
PSDIAVEW
DIAVEWESNGQPE
QPENNYKTTPPMLDSDGSFFLYSKLTVDKSR
PENNYKTTPPMLDSDGSFFLYSKLTVDKSR
TTPPMLD
TTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
FFLYSKLTVDKSRWQQGNVF
LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL
KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL
TVDKSRWQQGNVFSCSVMH
# Generated sample - 10106H|ascrinvacumab|Homo sapiens||H-GAMMA-2 (VH (1-118) [D1] + CH1 (119-216) [D2] + CH2 (229-337) [D3] + CH3 (338-442) [D4])|||||||444|444|||MW undefined|MW undefined| - Alfalytic protease - 75%
GFDYWGQGT
KDYFPEPV
ERKCCV
ECPPCPA
FLFPPKPKDT
HEDPEV
QFNWYV
HQDWLNGKEYKCKV
NKGLPA
NGQPENNYKT
PPMLDS
RWQQGNV
# Generated sample - 10106L|ascrinvacumab|Homo sapiens||L-KAPPA (V-KAPPA (1-108) [D1] + C-KAPPA (109-215) [D2])|||||||215|215|||MW undefined|MW undefined| - Trypsin - 75%
EIVLTQSPGTLSLSPGER
ATLSCR
ASQSVSSSYLAWYQQKPGQAPR
LLIYGTSSR
FSGSGSGTDFTLTISR
LEPEDFAVYYCQQYGSSPITFGQGTR
TVAAPSVFIFPPSDEQLK
SGTASVVCLLNNFYPR
VDNALQSGNSQESVTEQDSK
DSTYSLSSTLTLSK
VYACEVTHQGLSSPVTK
# Generated sample - 10106L|ascrinvacumab|Homo sapiens||L-KAPPA (V-KAPPA (1-108) [D1] + C-KAPPA (109-215) [D2])|||||||215|215|||MW undefined|MW undefined| - Chymotrypsin - 75%
TQSPGTL
SCRASQSVSSSY
QQKPGQAPRL
GTSSRATGIPDRF
SGSGSGTDF
GSSPITF
GQGTRL
EIKRTVAAPSVF
PPSDEQL
PREAKVQW
KVDNAL
QSGNSQESVTEQDSKDSTY
EKHKVY
ACEVTHQGL
# Generated sample - 10106L|ascrinvacumab|Homo sapiens||L-KAPPA (V-KAPPA (1-108) [D1] + C-KAPPA (109-215) [D2])|||||||215|215|||MW undefined|MW undefined| - LysC - 75%
RTVAAPSVFIFPPSDEQLK
SGTASVVCLLNNFYPREAK
DSTYSLSSTLTLSK
VYACEVTHQGLSSPVTK
SFNRGEC
# Generated sample - 10106L|ascrinvacumab|Homo sapiens||L-KAPPA (V-KAPPA (1-108) [D1] + C-KAPPA (109-215) [D2])|||||||215|215|||MW undefined|MW undefined| - Aspecific - 75%
VLTQSPGTLSLSPGERATLSCRASQ
TQSPGTLSLSPGERATLSCRASQSVSSSYLAWY
SPGTLSLSPGERATLSCRASQ
PGTLSLSPGE
SLSPGERATLSCRASQSVSSSYL
SPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGT
CRASQSVSSSYLAWYQQKPG
ASQSVSSSYLAWYQQKPGQAPRLLIYG
SQSVSSS
QSVSSSYLAWYQQK
LAWYQQKPGQAPRLLIYGTSSRATGIPDRFSGSGSGTD
WYQQKPGQAPRLLIYGTSSRATGIPDRFS
YQQKPGQAPRLLIYGTSSRATGIPDRFSGSGSG
GQAPRLLIYGTSSRATGIPDR
RLLIYGTSSRATGIPDRFSGSGSGT
IYGTSSRATGIPDRFSGSGSGTDFTLTISRLE
GTDFTLTISRLEPEDFAVYYCQQYGSSPIT
TDFTLTISRLEPEDFAVYYCQQYGSSP
SRLEPEDFAVYYCQQYGSSP
RLEPEDFAVYYCQQYGSSPITFG
RLEPEDFAVYYCQQYGSSPITFGQGTRLEIKR
PEDFAVYYCQQYGSSPIT
RLEIKRTVAAPSVFIFPPSDEQLKSGTASVVC
LEIKRTVAAPSVFIF
EIKRTVAAPS
EIKRTVAAPSVFIFPPSDEQLK
VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWK
APSVFIFPPS
PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
FIFPPSDEQLKS
FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN
IFPPSDEQLKSGTASV
LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES
GTASVVC
SVVCLLNNFYPREAKVQ
AKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSK
QSGNSQES
GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE
QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
DSKDSTYSLSSTL
HQGLSSPVTKSFNR
LSSPVTKSFNRGE
# Generated sample - 10106L|ascrinvacumab|Homo sapiens||L-KAPPA (V-KAPPA (1-108) [D1] + C-KAPPA (109-215) [D2])|||||||215|215|||MW undefined|MW undefined| - Alfalytic protease - 75%
PRLLIYGT
GIPDRFS
RLEPEDFA
YYCQQYGS
RLEIKRT
FIFPPS
DEQLKS
CLLNNFYPREA
DYEKHKV
FNRGEC
